RSS Facebook Twitter YouTube

Lymphomas

Phase 2 study of daratumumab in NHL won’t proceed

HT Staff Read Article
Published: 03/31/17

daratumumab-230.jpg
Daratumumab (Darzalex)
Photo courtesy of Janssen

The phase 2 CARINA study of daratumumab in non-Hodgkin lymphoma (NHL) will not proceed to stage 2, according to Genmab A/S and Janssen Biotech, Inc. In this study, researchers have been investigating daratumumab monotherapy in patients with relapsed or refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), or mantle cell lymphoma (MCL). Researchers planned to enroll up to 210 patients in the 3 disease cohorts in 2 stages. [Read Article]

FDA lifts partial clinical hold for some selinexor trials

HT Staff Read Article
Published: 03/30/17

preparing_capsules_for_a_clinical_trial_credit_Esther_Dyson_230.jpg
Preparing treatment for a trial
Photo by Esther Dyson

The US Food and Drug Administration (FDA) has lifted the partial clinical hold on trials of selinexor (KPT-330) in patients with hematologic malignancies. The partial clinical hold, which was announced on March 10, was placed on all trials of the drug, including studies of patients with solid tumor malignancies. The hold meant that no new patients could be enrolled in selinexor trials. Patients who were already enrolled and had stable disease or better could remain on selinexor therapy.  [Read Article]

Inpatient palliative care improves QOL for HSCT patients

Erilyn Riley Read Article
Published: 02/27/17

doctor_and_hospitalized_patient_smiling_Credit_CDC_230.jpg
Doctor and hospitalized patient
Photo courtesy of CDC

New research shows that patients who received inpatient palliative care while undergoing hematopoietic stem cell transplant (HSCT) experienced significant improvements in quality of life (QOL), decreases in depression, and reductions in symptom burden compared to patients who received transplant care alone. Areej R. El-Jawahri, MD, of Harvard Medical School in Boston, Massachusetts, presented these results at the 2017 BMT Tandem Meetings. [Read Article]

CHMP recommends authorization of antiemetic agent

HT Staff Read Article
Published: 02/27/17

patient_receives_chemo_older_woman_Credit_Rhoda_Baer_220.jpg
Cancer patient
receiving chemotherapy
Photo by Rhoda Baer

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiemetic agent rolapitant (Varuby) as a treatment for adults with cancer. The drug is intended to be used in combination with other antiemetic agents to prevent delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. [Read Article]

Drug granted orphan status for follicular lymphoma

HT Staff Read Article
Published: 02/24/17

follicular-lymphoma-230.jpg
Micrograph showing
follicular lymphoma

The US Food and Drug Administration (FDA) has granted orphan designation to G100 for the treatment of follicular lymphoma. G100 is a synthetic small-molecule toll-like receptor-4 agonist, glucopyranosyl lipid A, formulated in a stable emulsion. The FDA grants orphan designation to drugs and biologics intended to treat, diagnose, or prevent rare diseases/disorders affecting fewer than 200,000 people in the US. [Read Article]

 

{title}

{icon} {author} Read Article
Published: {pubDate}

{summary}